Acalabrutinib Plus Bendamustine and Rituximab in Untreated MCL: Results From the Phase 3 ECHO Trial : Episode 2
Phase 3 ECHO Trial: Study Design and Efficacy Data
The panelists evaluate the preliminary efficacy findings from the ECHO trial and address how the COVID-19 pandemic influenced overall survival outcomes in the study.
- What are your initial impressions of the efficacy data from ECHO?
- How did COVID impact OS for this trial data?
- Do you have clinical experience with BTKi’s in the frontline setting?
- If so, please share your experience.
Recent Videos
Related Content
Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies
Viviana Cortlana, PGY-4;Jade Gambill, BSc;Jenna Ghazal, BSc;Kennedy Itodo;Shreevikaa Kannan, PGY-5;Yan Leyfman, MD;Chandler H. Park, MD, FACP
March 7th 2025Article
Several lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025Podcast
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
